← Back to Search

Protease Inhibitor

GW433908/Ritonavir vs. Lopinavir/Ritonavir for HIV

Phase 3

Waitlist Available

Research Sponsored by GlaxoSmithKline

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients who have taken protease inhibitors (PIs) for at least 12 straight weeks and have had virologic failure on the PIs

Patients who are currently taking antiretroviral therapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will test two different drug regimens to see which is more effective in patients who have not had success with other anti-HIV drugs.

Who is the study for?

This trial is for HIV patients who've previously taken protease inhibitors and experienced treatment failure. Participants must have a viral load over 1,000 copies/ml, be at least 13 years old (or meet local age requirements), and if female, not be pregnant and agree to use birth control. Exclusions include those with significant kidney or bone disease, substance abuse issues, certain allergies or serious health conditions.Check my eligibility

What is being tested?

The study compares two dosing regimens of GW433908/ritonavir versus lopinavir/ritonavir when each is combined with two active reverse transcriptase inhibitors in patients who have had unsuccessful anti-HIV treatments.See study design

What are the potential side effects?

Potential side effects may include digestive issues, liver problems like hepatitis or pancreatitis (especially if there's a history), allergic reactions to the drugs involved, changes in blood tests that could indicate other organ issues, fatigue from drug interactions affecting overall health.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been on protease inhibitors for 12 weeks but they failed to control my virus.

Select...

I am currently on antiretroviral therapy.

Select...

I am at least 13 years old (or 18 if required) and can provide parental consent if under 18.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

GlaxoSmithKlineLead Sponsor

4,750 Previous Clinical Trials

8,067,122 Total Patients Enrolled

Media Library

GW433908 (Protease Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00025727 — Phase 3

Human Immunodeficiency Virus Infection Research Study Groups:

Human Immunodeficiency Virus Infection Clinical Trial 2023: GW433908 Highlights & Side Effects. Trial Name: NCT00025727 — Phase 3

GW433908 (Protease Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00025727 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do we have any octogenarians in the study?

"This trial is recruiting patients who are older than 13 years old and less than 0 years of age."

Answered by AI

Has this medication received government sanctioning?

"Our analysts have determined that this Phase 3 trial's safety merits a score of 3. This is based on supporting efficacy data as well as multiple rounds of data affirming the treatment's safety."

Answered by AI